STOCK TITAN

Aura Biosciences (AURA) director receives RSU and 60,000 stock option grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Aura Biosciences, Inc. director Jeremy Bender reported equity awards consisting of restricted stock units and stock options as part of his compensation. He received 30,000 shares of Common Stock through an RSU award, with each unit representing one share. These RSUs vest in three substantially equal annual installments beginning on July 15, 2027, subject to his continued service.

He was also granted 60,000 stock options to purchase Common Stock at an exercise price of $7.03 per share, expiring on July 7, 2036. The option vests in three substantially equal annual installments beginning on July 7, 2027, conditioned on his continued service. After these awards, he holds 30,000 shares of Common Stock and 60,000 stock options directly.

Positive

  • None.

Negative

  • None.
Insider Bender Jeremy
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 60,000 $0.00 --
Grant/Award Common Stock 30,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 60,000 shares (Direct, null); Common Stock — 30,000 shares (Direct, null)
Footnotes (1)
  1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in three substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service as of each such vesting date. The shares underlying this option vest in three substantially equal annual installments beginning on July 7, 2027, subject to the Reporting Person's continued service as of each such vesting date.
RSU grant 30,000 shares Restricted stock units representing Common Stock
Option grant 60,000 options Stock Option (Right to Buy) underlying Common Stock
Option exercise price $7.03 per share Conversion or exercise price for stock options
RSU vesting start July 15, 2027 First of three annual RSU vesting dates
Option vesting start July 7, 2027 First of three annual option vesting dates
Option expiration July 7, 2036 Expiration date of stock options
Shares after award 30,000 shares Total Common Stock held following RSU acquisition
Options after award 60,000 options Total stock options held following grant
restricted stock unit ("RSU") financial
"These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan."
2021 Stock Option and Incentive Plan financial
"These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan."
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
vest in three substantially equal annual installments financial
"These RSUs vest in three substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service."
exercise price financial
"conversion_or_exercise_price": "7.0300""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Jeremy Bender acquire in this Aura Biosciences (AURA) Form 4?

Jeremy Bender received equity compensation awards, not open-market trades. He acquired 30,000 restricted stock units and 60,000 stock options, both tied to Aura Biosciences’ Common Stock, subject to multi-year vesting and continued service conditions.

How many Aura Biosciences (AURA) RSUs were granted to Jeremy Bender?

He was granted 30,000 restricted stock units, each representing one share of Aura Biosciences Common Stock. These RSUs vest in three substantially equal annual installments starting July 15, 2027, provided he remains in service on each vesting date.

What are the terms of Jeremy Bender’s Aura Biosciences (AURA) stock options?

He received 60,000 stock options with an exercise price of $7.03 per share. The options vest in three substantially equal annual installments beginning July 7, 2027, and expire on July 7, 2036, assuming continued service.

Are Jeremy Bender’s Aura Biosciences (AURA) awards immediately vested or subject to conditions?

Both awards are subject to vesting conditions. The 30,000 RSUs and 60,000 stock options each vest in three substantially equal annual installments starting in 2027, contingent on Jeremy Bender’s continued service through each vesting date.

Did Jeremy Bender buy or sell Aura Biosciences (AURA) shares in the market?

No open-market buying or selling is reported. The Form 4 shows compensation-related acquisitions: 30,000 RSUs and 60,000 stock options granted at no cash cost to him, with vesting based on continued service.

What are Jeremy Bender’s Aura Biosciences (AURA) holdings after these transactions?

Following the reported awards, Jeremy Bender directly holds 30,000 shares of Aura Biosciences Common Stock and 60,000 stock options, according to the Form 4 figures provided for post-transaction ownership.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bender Jeremy

(Last)(First)(Middle)
C/O AURA BIOSCIENCES, INC.
80 GUEST STREET

(Street)
BOSTON MASSACHUSETTS 02135

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Aura Biosciences, Inc. [ AURA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/07/2026A30,000(1)A$030,000D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$7.0307/07/2026A60,000 (2)07/07/2036Common Stock60,000$060,000D
Explanation of Responses:
1. These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in three substantially equal annual installments beginning on July 15, 2027, subject to the Reporting Person's continued service as of each such vesting date.
2. The shares underlying this option vest in three substantially equal annual installments beginning on July 7, 2027, subject to the Reporting Person's continued service as of each such vesting date.
/s/ Conor Kilroy, as Attorney-in-Fact07/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)